- Details
- Oliver Sartor discusses the REASSURE study with Alicia Morgans. The study investigates the long-term side effects of radium, the first approved alpha emitter, on prostate cancer patients. With over 1,400 patients involved, the study monitors side effects such as fractures, bone marrow failure, and secondary malignancies over the course of years. Interestingly, the study found fewer side effects th...
|
- Details
- In a discussion hosted by Andrea Miyahira, David Quigley discusses his team's research on the genomic and epigenomic landscape of double-negative metastatic prostate cancer. Dr. Quigley provides insights into the mechanisms behind the disease's resistance to targeted therapy, highlighting the transformation of prostate adenocarcinoma cells towards either maintaining their original nature or transi...
|
- Details
- Phillip Koo and Daniel Saltzstein delve into the ECLIPSE clinical trial. The trial, aiming to enroll over 400 patients, brings Lutetium-177, a radioligand therapy, to patients with metastatic castrate-resistant prostate cancer at an earlier stage than it's currently approved for. Dr. Saltzstein outlines the trial's inclusion criteria, notably patients with castrated testosterone, PSA progression,...
|
- Details
- David VanderWeele elucidates findings from the TALAPRO-2 study, emphasizing the substantial hazard ratio benefits observed in metastatic CRPC patients with HRR mutations, especially those with BRCA1 and 2 mutations, treated with enzalutamide combined with talazoparib. However, he raises questions regarding the true representation of the trial's population and a lack of subsequent PARP inhibitor tr...
|
- Details
- Alicia Morgans converses with Ravi Madan about an ongoing trial involving patients with biochemical recurrence of prostate cancer. The unique trial utilizes Prostate-Specific Membrane Antigen (PSMA) PET imaging to routinely monitor patients and to develop an understanding of the natural history of the disease in the context of recurrent prostate cancer. The goal is to prospectively monitor these p...
|
- Details
- Alicia Morgans hosts Sumit Subudhi to discuss underutilized therapies for metastatic castration-resistant prostate cancer (mCRPC). Dr. Subudhi expounds on the complexities of Sipuleucel-T and Radium-223, highlighting their benefits for maintaining patient quality of life. He clarifies that while these therapies do not reduce prostate-specific antigen (PSA) levels, they slow down cancer growth, exp...
|
- Details
- Alicia Morgans welcomes Boris Hadaschik to discuss the implications of using PSMA PET in non-metastatic castration-resistant prostate cancer treatment. Their focus lies on Dr. Hadaschik's presentation examining the long-term outcomes and clinical implications of this technology. His study refers to a 2019 dataset involving 200 men diagnosed with high-risk non-metastatic CRPC. Dr. Hadaschik explain...
|
- Details
- Alicia Morgans and Daniel Sentana Lledo discuss a groundbreaking analysis on data from the CHAARTED study that examined how quality of life impacts survival in metastatic hormone-sensitive prostate cancer patients. Interestingly, patients with better quality of life scores at three months exhibited longer survival times. However, the role of docetaxel (a chemotherapeutic) treatment in this finding...
|
- Details
- Alicia Morgans hosts Tian Zhang to present an update from her presentation on the STARTAR trial, focusing on treatment intensification for high-risk prostate cancer with biochemical recurrence. STARTAR builds on an earlier trial, STREAM, by combining hormone deprivation with apalutamide, salvage radiation, and six cycles of docetaxel. The study focused on patients with Gleason 7 with nodal positiv...
|
- Details
- Andrea Miyahira and Susan Halabi discuss Dr Halabi's prognostic model for overall survival in patients with metastatic castration-resistant prostate cancer. Originating in the early 2000s, the model sought to provide patients with more specific information about their prognoses and categorize them into different risk groups. Dr. Halabi's model comprises eight easily obtainable clinical variables,...
|
